Linked Life Data

17680564

Source:http://linkedlifedata.com/resource/pubmed/id/17680564

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2007-10-2
pubmed:abstractText
Interferon alpha is used for the adjuvant treatment of malignant melanoma at different dosages (high-, intermediate-, low-dose therapy). Only a minority of patients might benefit from this therapy, and markers to identify such patients are missing. A recent study suggested that melanoma patients developing autoantibodies or clinical manifestations of autoimmunity during adjuvant high-dose interferon alpha treatment had a significant survival benefit. We retrospectively reviewed 134 melanoma patients from our institution treated with adjuvant low-dose interferon alpha therapy and correlated the development of autoimmune diseases with prognosis. Interferon (IFN) therapy was routinely monitored by history, physical examination and laboratory tests before, after the first month and then after every 3 months of therapy. During a median follow up of 46.0 months (8.5-79.0 months) 28 patients (20.9%) suffered from recurrences and melanoma related deaths occurred in 16 patients (11.9%). In 20 patients (14.9%) autoimmune thyroiditis (AIT) was diagnosed during IFN therapy, one of these 20 patients developed rheumatoid arthritis later while continuing IFN therapy. Other autoimmune diseases were not observed. In 2 patients (one with AIT and one with arthritis) the autoimmune disease led to discontinuation of IFN therapy, in the other patients AIT remained subclinical or responded well to treatment while IFN therapy was continued. Kaplan-Meier analyses revealed a significant better recurrence free survival and a trend for a better overall survival for patients with AIT. Thus, autoimmunity triggered by low-dose IFN therapy appears to indicate an improved prognosis and should encourage continuation of IFN therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
1097-0215
pubmed:author
pubmed:copyrightInfo
(c) 2007 Wiley-Liss, Inc.
pubmed:issnType
Electronic
pubmed:day
1
pubmed:volume
121
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2562-6
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:17680564-Adult, pubmed-meshheading:17680564-Aged, pubmed-meshheading:17680564-Antineoplastic Agents, pubmed-meshheading:17680564-Autoantibodies, pubmed-meshheading:17680564-Autoimmunity, pubmed-meshheading:17680564-Chemotherapy, Adjuvant, pubmed-meshheading:17680564-Drug Administration Schedule, pubmed-meshheading:17680564-Female, pubmed-meshheading:17680564-Humans, pubmed-meshheading:17680564-Interferon-alpha, pubmed-meshheading:17680564-Kaplan-Meier Estimate, pubmed-meshheading:17680564-Male, pubmed-meshheading:17680564-Melanoma, pubmed-meshheading:17680564-Middle Aged, pubmed-meshheading:17680564-Predictive Value of Tests, pubmed-meshheading:17680564-Prognosis, pubmed-meshheading:17680564-Recombinant Proteins, pubmed-meshheading:17680564-Research Design, pubmed-meshheading:17680564-Retrospective Studies, pubmed-meshheading:17680564-Risk Factors, pubmed-meshheading:17680564-Skin Neoplasms, pubmed-meshheading:17680564-Treatment Outcome
pubmed:year
2007
pubmed:articleTitle
Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
pubmed:affiliation
Department of Dermatology and Allergology, Hannover Medical School, Hautklinik Linden, Klinikum Region Hannover, Skin Cancer Center Hannover, Hannover, Germany.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't